CO2022005587A2 - Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas - Google Patents

Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas

Info

Publication number
CO2022005587A2
CO2022005587A2 CONC2022/0005587A CO2022005587A CO2022005587A2 CO 2022005587 A2 CO2022005587 A2 CO 2022005587A2 CO 2022005587 A CO2022005587 A CO 2022005587A CO 2022005587 A2 CO2022005587 A2 CO 2022005587A2
Authority
CO
Colombia
Prior art keywords
siglec
methods
fusion molecules
ecd fusion
ecd
Prior art date
Application number
CONC2022/0005587A
Other languages
English (en)
Inventor
Spencer Liang
Samuel Nalle
Jeonghoon Sun
Hua Long
Rashmi Bankoti
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of CO2022005587A2 publication Critical patent/CO2022005587A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Recrystallisation Techniques (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción se refiere generalmente al ECD de Siglec-9 o moléculas de fusión del ECD de Siglec-9, y a métodos de tratamiento que usan ECD de Siglec-9 y moléculas de fusión del ECD de Siglec-9.
CONC2022/0005587A 2019-11-04 2022-04-29 Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas CO2022005587A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962930227P 2019-11-04 2019-11-04
US202063014940P 2020-04-24 2020-04-24
US202063092753P 2020-10-16 2020-10-16
PCT/US2020/058687 WO2021091885A2 (en) 2019-11-04 2020-11-03 Siglec-9 ecd fusion molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2022005587A2 true CO2022005587A2 (es) 2022-07-29

Family

ID=73598983

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0005587A CO2022005587A2 (es) 2019-11-04 2022-04-29 Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas

Country Status (17)

Country Link
US (1) US11987612B2 (es)
EP (1) EP4055031A2 (es)
JP (1) JP2022553571A (es)
KR (1) KR20220092918A (es)
CN (1) CN114667298A (es)
AU (1) AU2020378251A1 (es)
BR (1) BR112022008321A2 (es)
CA (1) CA3155345A1 (es)
CL (1) CL2022001130A1 (es)
CO (1) CO2022005587A2 (es)
CR (1) CR20220244A (es)
EC (1) ECSP22044316A (es)
IL (1) IL292499A (es)
MX (1) MX2022005376A (es)
PE (1) PE20221271A1 (es)
TW (1) TW202132329A (es)
WO (1) WO2021091885A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230167103A1 (en) 2020-04-24 2023-06-01 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2024102635A1 (en) * 2022-11-07 2024-05-16 Alector Llc Uses of siglec-9 ecd fusion molecules in cancer treatment

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
GB0521991D0 (en) 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
WO2007120815A2 (en) 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CN104302665B (zh) 2011-12-21 2019-04-23 安姆根有限公司 与新生儿Fc受体的结合增强的变体Fc多肽
JP6403062B2 (ja) 2012-12-21 2018-10-10 国立大学法人徳島大学 組織修復活性組成物及びその利用
WO2014120642A1 (en) 2013-01-30 2014-08-07 The General Hospital Corporation Diagnosis and treatment of hepatorenal syndrome
US20170306014A1 (en) 2014-09-10 2017-10-26 Innate Pharma Cross reactive siglec antibodies
BR112017023692A2 (pt) 2015-05-01 2018-07-17 The Regents Of The University Of California moléculas imunoterapêuticas glican-dependentes
JP7060502B2 (ja) * 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
US10634656B2 (en) 2015-10-30 2020-04-28 Hach Company Storage stable standards for aqueous chlorine analysis
CA3004972A1 (en) * 2015-11-17 2017-05-26 Innate Pharma Siglec-10 antibodies
WO2017123745A1 (en) 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
CN108699158B (zh) 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
GB201611535D0 (en) 2016-07-01 2016-08-17 King's College London Methods and compositions for treating cancer with siglec-9 activity modulators
JP2019527204A (ja) 2016-07-01 2019-09-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抑制性免疫受容体阻害方法および組成物
KR20200026254A (ko) 2017-07-10 2020-03-10 이나뜨 파르마 암을 치료하기 위해 인간 siglec-9 에 대한 항체 및 인간 nkg2a 에 대한 항체를 사용하는 조합 치료요법
CA3066514A1 (en) 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
AU2019282825A1 (en) 2018-06-07 2020-12-10 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
AU2019293600A1 (en) 2018-06-29 2021-01-14 Verseau Therapeutics, Inc. Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
AU2019353000A1 (en) 2018-10-02 2021-06-03 Obi Pharma, Inc. Combination therapy using anti-SSEA-4 antibody in combination with therapeutic oncology agents
US20220211831A1 (en) 2019-04-17 2022-07-07 Bar-Ilan University Siglec-based chimeric polypeptides and uses thereof
EP3980462A4 (en) 2019-06-04 2023-09-20 Verseau Therapeutics, Inc. ANTI-SIGLEC-9 COMPOSITIONS AND METHODS OF MODULATING INFLAMMATORY PHENOTYPES OF MYELOID CELLS AND RELATED USES
WO2021011377A2 (en) 2019-07-12 2021-01-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of enhancing immunogenicity of cancers

Also Published As

Publication number Publication date
JP2022553571A (ja) 2022-12-23
AU2020378251A1 (en) 2022-05-26
CR20220244A (es) 2022-06-28
US20210284710A1 (en) 2021-09-16
MX2022005376A (es) 2022-05-19
WO2021091885A2 (en) 2021-05-14
CN114667298A (zh) 2022-06-24
KR20220092918A (ko) 2022-07-04
CA3155345A1 (en) 2021-05-14
TW202132329A (zh) 2021-09-01
WO2021091885A3 (en) 2021-06-17
ECSP22044316A (es) 2022-07-29
CL2022001130A1 (es) 2023-02-24
IL292499A (en) 2022-06-01
US11987612B2 (en) 2024-05-21
EP4055031A2 (en) 2022-09-14
PE20221271A1 (es) 2022-09-01
BR112022008321A2 (pt) 2022-07-26

Similar Documents

Publication Publication Date Title
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CO2017009060A2 (es) Polipéptido hibrido de la enzima de degradación inmunoglobulina g del s. pyogenes y enzima de degradación de inmunoglobulina g del streptococcus equi ssp. zooepidemicus
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
DOP2020000245A (es) Anticuerpos il-11
DOP2020000021A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CL2022001130A1 (es) Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
PH12020552229A1 (en) Il-11ra antibodies
CL2023001550A1 (es) Sistemas activos dinámicos acromosómicos.
BR112017017284A2 (pt) protease de cisteína
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
AU2016263598A8 (en) Methods and kits for treating depression
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
CL2016002827A1 (es) Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos.
BR112018070188A2 (pt) uso de caulim como opacificante
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
CR20190471A (es) Moduladores de la expresión de pcsk9